• Otofarma’s hearing aid sales rose 8.4% to 8,811 units in the first nine months of 2026.
• Pharmacy-channel sales increased 3.4% to 7,636 units, remaining the largest distribution channel.
• Optical-channel sales surged 607% to 403 units, supporting distribution diversification.
• The affiliated optical network reached 357 locations at September 30, up 104% from year-end 2025.
• Specialist telemedicine services increased 255.3% to 4,018 consultations.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Otofarma S.p.A. published the original content used to generate this news brief via SDIR, the Italian regulatory disclosure system (Ref. ID: 20343-27-2026_TELEBORSA.pdf), on October 23, 2026, and is solely responsible for the information contained therein.